Posts

Posted on

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

  • LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune disease
  • LISRAYA is a once-daily pill that directly targets key immune pathways implicated in dermatomyositis pathogenesis
  • LISRAYA demonstrated robust efficacy on multiple measures of DM disease activity, accompanied by substantial steroid-sparing benefits, in the largest dermatomyositis clinical trial ever conducted
  • LISRAYA is available immediately in the U.S.
  • Eligible patients may pay as little as $0 per month through the LISRAYA My Compass Support program.

DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) — Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.

DM is a rare systemic autoimmune disease characterized by progressive muscle weakness and extensive, painful, and pruritic skin lesions. DM significantly impairs patients’ quality of life through physical disability, pain from both muscle and skin disease, cutaneous disfigurement, skin sensitivity to light and touch, and high levels of dependency on chronic high-dose steroids.

LISRAYA, a first-in-class TYK2/JAK1 inhibitor, is the first and only targeted therapy approved for dermatomyositis. LISRAYA is proven to provide a wide array of efficacy benefits for adult DM patients, including improvements in skin disease, muscle strength, physical function, and overall disease burden, alongside substantial steroid-sparing benefit. LISRAYA can be prescribed by healthcare professionals in the United States effective immediately. Prescriptions can be submitted at lisrayahcp.com/enroll. Full prescribing information is available at lisrayahcp.com/pi.

“Dermatomyositis affects nearly every aspect of a patient’s life, causing physical disability, disfiguring skin disease, pain, itch, and a profound loss of independence and sense of self,” said Ruth Ann Vleugels, MD, MPH, MBA, Heidi and Scott C. Schuster Distinguished Chair in Dermatology, Founding Director of the Autoimmune Skin Disease Center and Connective Tissue Disease Clinics at Mass General Brigham, and Professor of Dermatology at Harvard Medical School.  “For many decades, the treatment of dermatomyositis has relied on chronic steroids, non-specific immunomodulators, and intravenous immunoglobulin—therapies not targeted to the underlying disease pathobiology. The approval of LISRAYA marks a turning point for patients living with dermatomyositis. For the first time, I am thrilled to be able to offer my patients a targeted, once-daily oral medicine that delivers meaningful benefit across muscle, skin, and overall disease activity while simultaneously reducing reliance on systemic corticosteroids.” 

LISRAYA’s approval follows the landmark Phase 3 VALOR trial, the largest DM trial ever conducted.

In the VALOR trial, benefits on the primary endpoint, the myositis Total Improvement Score (a composite measure designed to capture improvement across multiple disease domains), were seen as early as Week 4, increased over time, and were sustained to the end of the 52-week study. Most patients treated with LISRAYA were able to achieve both moderate or better improvement on the Total Improvement Score and minimal or no steroid use by the end of the study (55%, compared to 30% on placebo), underscoring LISRAYA’s ability to simultaneously improve disease symptoms and reduce steroid dependency. Among patients receiving LISRAYA who were taking ≥7.5 mg/day (prednisone-equivalent) of oral corticosteroids at baseline, 62% tapered to minimal or no steroid use (≤2.5 mg/day) by the end of the 52-week study, compared with 38% on placebo; 45% came off corticosteroids entirely, compared with 29% on placebo.

LISRAYA also demonstrated benefit on independent measures of skin disease and muscle strength, and, critically, on endpoints that directly capture patients’ own experience living with dermatomyositis. When asked to rate the overall activity of their disease, patients receiving LISRAYA reported more than four times as much improvement as patients on placebo. On a measure of everyday function – including pain and core activities of daily living such as getting dressed, climbing stairs, and running errands – patients treated with LISRAYA achieved clinically meaningful improvement, while those receiving placebo worsened, highlighting LISRAYA’s ability to restore greater independence and personal agency to DM patients’ lives.

The most common adverse reactions for patients on LISRAYA in the VALOR trial were upper respiratory tract infection, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, fall, influenza, and acne. See important LISRAYA safety information below and full safety information, including boxed warning, at lisrayahcp.com/pi.

Primary results from the VALOR trial were published in the New England Journal of Medicine in March 2026, with additional skin-specific secondary endpoints published in JAMA Dermatology in August 2026.

LISRAYA is indicated for the treatment of dermatomyositis in adults. It can be used for adult DM patients with no restrictions based on their level of disease activity, clinical presentation, or prior treatment experience. LISRAYA can be used as an alternative therapy or add-on therapy to non-targeted DM treatments used today, depending on specific patient needs. Notably, the Phase 3 VALOR study evaluated the efficacy and safety of LISRAYA across patients on a wide array of different combinations of background therapies, including no background therapy.

Priovant is committed to helping patients access LISRAYA as quickly as possible. LISRAYA is available through a limited distribution network of specialty pharmacies. Patients can enroll in LISRAYA My Compass Support, which offers personalized assistance from a dedicated Patient Access Liaison, including help with insurance coverage, financial assistance programs, and ongoing support throughout the treatment journey. Through My Compass Support, eligible patients may pay as little as $0 per month for LISRAYA. Patients can enroll in My Compass Support at lisraya.com/enrollment.

“Today’s approval of LISRAYA marks a historic moment for the dermatomyositis community and reflects years of extraordinary work and sacrifice by the team at Priovant, our partners, and, above all, the investigators and patients who participated in the brepocitinib development program,” said Ben Zimmer, Chief Executive Officer of Priovant. “I am thrilled that adults with dermatomyositis finally have a fundamentally new treatment option – one specifically designed to target the biology of their disease and shown to meaningfully improve how patients feel and function in their daily lives.”    

FDA approval of LISRAYA follows the agency’s prior granting of Priority Review and Orphan Drug Designation. Priority Review is reserved for medicines that, if approved, would provide significant improvements in safety or efficacy for treatment of a serious condition.


LISRAYA IMPORTANT SAFETY INFORMATION and INDICATION AND USAGE

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR
ADVERSE

CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS

INDICATIONS AND USAGE
LISRAYA (brepocitinib) is indicated for the treatment of adults with dermatomyositis (DM).

Limitations of Use

Not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.

WARNINGS and PRECAUTIONS
:

Serious infections. Patients treated with LISRAYA are at increased risk of developing serious bacterial, fungal, viral, and opportunistic infections that may lead to hospitalization or death.
Reported infections with use of Janus kinase (JAK) inhibitors, including LISRAYA:

  • Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Evaluate and test patients for latent and active TB infection prior to and during LISRAYA treatment. If positive, treat for TB. Monitor all patients for active TB during treatment including patients who tested negative for a latent TB infection prior to LISRAYA treatment.
  • Invasive fungal infections. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
  • Bacterial, viral (including herpes zoster), and other infections due to opportunistic pathogens.

Avoid use of LISRAYA in patients with an active, serious infection, including localized infections. Consider the risks and benefits of LISRAYA in patients with chronic or recurrent infection prior to initiating treatment. Closely monitor patients for signs and symptoms of infection during and after treatment with LISRAYA. If a serious infection occurs, interrupt LISRAYA treatment until the infection resolves or is adequately treated.

Mortality. A higher rate of all-cause mortality, including sudden cardiovascular death, was observed with another Janus kinase (JAK) inhibitor when compared to tumor necrosis factor (TNF) blockers in patients with rheumatoid arthritis (RA) 50 years of age and older with at least one cardiovascular risk factor. LISRAYA is not approved for use in patients with RA.

Malignancy. Malignancies have occurred in patients treated with LISRAYA. A higher rate of malignancies (excluding non-melanoma skin cancer), lymphomas, and lung cancers was observed with another JAK inhibitor when compared to TNF blockers in patients with RA. LISRAYA is not approved for use in patients with RA. Patients who are current or past smokers are at additional increased risk.

Major Adverse Cardiovascular Events (MACE). Major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) have occurred in patients treated with LISRAYA. A higher rate of MACE was observed with another JAK inhibitor when compared to TNF blockers in patients with RA 50 years of age and older with at least one cardiovascular risk factor. LISRAYA is not approved for use in patients with RA. Patients who are current or past smokers are at additional increased risk. Discontinue LISRAYA in patients who have experienced a myocardial infarction or stroke.

Thrombosis. Thromboses, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated for inflammatory conditions with JAK inhibitors, including LISRAYA. Many of these adverse reactions were serious and some resulted in death. A higher rate of thromboses was observed with another JAK inhibitor when compared to TNF blockers in patients with RA 50 years of age and older with at least one cardiovascular risk factor. LISRAYA is not approved for use in patients with RA. Avoid LISRAYA in patients who may be at risk of thrombosis. If symptoms of thrombosis occur, discontinue LISRAYA, promptly evaluate, and appropriately treat.

Hypersensitivity. LISRAYA is contraindicated in patients with known hypersensitivity to brepocitinib or any of its excipients. Hypersensitivity reactions were reported in patients receiving LISRAYA. Some events were serious.

Gastrointestinal Perforations. Gastrointestinal perforation has been reported in patients treated with JAK inhibitors, including LISRAYA. Monitor LISRAYA-treated patients who may be at risk for gastrointestinal perforation.

Hypoglycemia in Patients with Diabetes. LISRAYA may cause hypoglycemia in patients with diabetes. Hypoglycemia, including severe hypoglycemia, has been reported following initiation of JAK inhibitors in patients with diabetes. During treatment with LISRAYA, consider increased monitoring of blood glucose as clinically indicated in patients with diabetes.

Laboratory Abnormalities. LISRAYA has been associated with lab abnormalities including neutropenia, lymphopenia, anemia, increases in lipid parameters, and liver enzyme elevations.

Immunizations. Avoid use of live vaccines during or immediately prior to LISRAYA therapy initiation. Prior to initiating LISRAYA treatment, update immunizations, including prophylactic varicella zoster or herpes zoster vaccinations, according to current immunization guidelines.

Embryofetal Toxicity. Based on findings in animal studies, LISRAYA may cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to starting treatment. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LISRAYA and for 3 days following the last dose.

ADVERSE REACTIONS

The most common adverse reactions occurring in ≥5% of DM subjects and ≥2% greater than placebo were upper respiratory tract infection, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, fall, influenza, and acne.

SPECIAL POPULATIONS

Pregnancy. Based on findings in animal studies, LISRAYA may cause fetal harm when administered to a pregnant woman. Available data from LISRAYA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

Lactation. There are no data on the presence of brepocitinib in human milk, the effects on the breastfed infant, or the effects on milk production.

Hepatic Impairment. LISRAYA is not recommended in patients with severe hepatic impairment.

Renal Impairment. LISRAYA is not recommended in patients with severe renal impairment.

Please see the Full Prescribing Information, including BOXED WARNING, and Medication Guide.


About Priovant

Priovant Therapeutics is a biotechnology company dedicated to developing and commercializing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company’s commercial product, LISRAYA™ (brepocitinib) is the first and only targeted oral therapy approved for the treatment of adults with dermatomyositis. Brepocitinib, a first-in-class TYK2/JAK1 inhibitor, is also being evaluated in a Phase 3 program in non-infectious uveitis, a Phase 3 program in cutaneous sarcoidosis, and a Phase 2b/3 program in lichen planopilaris. Priovant Therapeutics is a Roivant (Nasdaq: ROIV) company.

Contacts:

© 2026 Priovant Therapeutics, Inc. All rights reserved. LISRAYA™ is the trademark of Priovant Therapeutics, Inc.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c9c8a80-2004-4328-82df-68a3d9e233f1



Posted on

JATT III Acquisition Corp Announces Closing of $69,000,000 Initial Public Offering

WESTFIELD, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) — JATT III Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,900,000 ordinary shares at an offering price of $10.00 per ordinary share on August 27, 2026, which includes 900,000 additional ordinary shares issued pursuant to the full exercise of the underwriters’ over-allotment option. Total gross proceeds from the offering were $69,000,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The ordinary shares began trading on the Nasdaq Global Market (“NASDAQ”) under the ticker symbol “JTTT” on August 26, 2026.

Guggenheim Securities, LLC acted as sole book-running manager.

AI Biotechnology LLC, an affiliate of Access Industries, Inc. and Vianti Capital Fund I, L.P. have indicated non-binding interests to participate in a private placement that may occur concurrently with the consummation of the Company’s initial business combination.

The offering included participation from Adage Capital Partners, L.P., ADAR1 Capital, Affinity Asset Advisors, LLC, Columbia Threadneedle Investments, Deep Track Capital, Great Point Partners, LLC, Janus Henderson Investors, Nantahala Capital, RA Capital Management, Sirenia Capital Management LP and Squadron Capital Management LLC and other institutional investors.

A registration statement relating to the securities sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 25, 2026. The public offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
JATT
I
II
Acquisition
Corp

JATT III Acquisition Corp is a newly incorporated blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. While the Company may pursue an initial business combination in any business or industry, the Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. In particular, the Company intends to seek businesses that can benefit from the clinical, scientific, operational, strategic and capital markets experience of the management team and board of directors and, in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing visibility with investors and potential partners. The Company expects to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process. The Company is sponsored by JATT Ventures III L.P. and is led by Dr. Someit Sidhu, Chief Executive Officer and Chairman of the Board, and Nicholas Fernandez, Chief Financial Officer. The Company’s Board of Directors also includes Verender S. Badial, Dr. Arjun Goyal, Dr. Jonathon Kluft and Christopher Staral, bringing extensive experience across biotechnology investing, company architecture, and public and private capital markets. Learn more at www.jattacquisition.com.

Forward-Looking
Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s initial public offering (“IPO”) including the gross proceeds of the IPO, the anticipated use of the net proceeds from the IPO and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or that the net proceeds of the offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of JATT III Acquisition Corp, including those set forth in the Risk Factors section of JATT III Acquisition Carp’s registration statement and prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. JATT III Acquisition Corp undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Nicholas Fernandez
Chief Financial Officer
153 Central Avenue C/O 56 Westfield, NJ 07091
201-688-0364



Posted on

Cathay Bank Celebrates Grand Opening of Ho Chi Minh City Representative Office

Cathay Bank Celebrates Grand Opening of Ho Chi Minh City Representative Office

LOS ANGELES–(BUSINESS WIRE)–
Cathay Bank celebrated a significant milestone in its expansion throughout the Asia-Pacific region with the grand opening of its Vietnam Representative Office on August 21 at Ho Chi Minh City. The new office is located in the Royal Center Building, Unit 606, 6th Floor, Royal Tower A, Royal Center Building, 235 Nguyen Van Cu, Cau Ong Lanh Ward, Ho Chi Minh City, 700000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827517075/en/

The grand opening ceremony was attended by senior leadership and community members who gathered to commemorate this significant occasion for Cathay Bank.

The grand opening ceremony was attended by senior leadership and community members who gathered to commemorate this significant occasion for Cathay Bank.

With this new office, Cathay Bank now has a total of four representative offices, including ones in Beijing, Shanghai, and Taipei, along with over 60 branches across the United States and a branch location in Hong Kong.

“We are pleased to expand our presence in Vietnam with the establishment of this Representative Office,” said Dunson K. Cheng, Executive Chairman of the Board of Cathay General Bancorp and Cathay Bank. “This opening marks an important step in the Bank’s ongoing international growth and demonstrates its long-term commitment to building meaningful relationships and serving communities across the Asia-Pacific region.”

The grand opening ceremony was attended by senior leadership and community members who gathered to commemorate this significant occasion for Cathay Bank.

For representative office inquiries, Hoai Anh Nguyen, Chief Representative of the Vietnam Office, can be reached directly at +84-283-622-5856 during normal business hours which are: Monday through Friday from 9:00 a.m. to 5:00 p.m.

About Cathay Bank

Cathay Bank, a subsidiary of Cathay General Bancorp (Nasdaq: CATY), opened its doors in 1962 in Los Angeles to serve the growing immigrant community. Today, we operate over 60 branches across the U.S., with a branch in Hong Kong, and representative offices in Beijing, Shanghai, Taipei, and Ho Chi Minh City. Learn more at cathaybank.com. FDIC insurance coverage is limited to deposit accounts at Cathay Bank’s U.S. domestic branch locations.

Diana Yang

626-279-3831

KEYWORDS: California North America United States Asia Pacific Viet Nam Southeast Asia

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Photo
Photo
The grand opening ceremony was attended by senior leadership and community members who gathered to commemorate this significant occasion for Cathay Bank.
Logo
Logo
Posted on

Stryker to participate in the 2026 Wells Fargo Healthcare Conference

Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor.

Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will also participate in a fireside chat session at 2:15 p.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker – Events & Presentations.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries:

Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]   

For media inquiries:

Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]



Posted on

Altria Increases Quarterly Dividend to $1.11 Per Share

Altria Increases Quarterly Dividend to $1.11 Per Share

RICHMOND, Va.–(BUSINESS WIRE)–
Altria Group, Inc. (Altria) (NYSE: MO) today announced that our Board of Directors voted to increase our regular quarterly dividend by 4.7% to $1.11 per share versus the previous rate of $1.06 per share.The quarterly dividend is payable on October 9, 2026 to shareholders of record as of September 15, 2026.

The new annualized dividend rate is $4.44 per share, representing a dividend yield of 6.4% based on our closing stock price of $69.12 on August 26, 2026.

Today’s dividend increase is consistent with our progressive dividend goal that targets mid-single digits dividend per share growth annually through 2028. This increase marks the 61st dividend increase in the past 57 years.

Altria Client Services

Investor Relations

(804) 484-8222

Altria Client Services

Media Relations

www.altria.com/contact-us/media

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Professional Services Retail Communications Tobacco Finance Other Communications

MEDIA:

Logo
Logo
Posted on

The New Miller® Copilot™ Builder™ With Blue iQ™ Brings Adaptive Automation to Real-World Fabrication Environments

The New Miller® Copilot™ Builder™ With Blue iQ™ Brings Adaptive Automation to Real-World Fabrication Environments

Adaptive-intelligence automation that adapts to changing fabrication conditions

APPLETON, Wis.–(BUSINESS WIRE)–Miller Electric Mfg. LLC, a leading manufacturer of arc welding equipment, today announced the launch of the Copilot Builder with Blue iQ, powered by NovAI™. Developed in collaboration with Novarc Technologies, the welding system is designed to help fabricators bring robotic welding to applications that have traditionally been difficult to automate due to part variation, fit-up inconsistencies, tack welds and the challenges associated with large, complex fabrications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827402562/en/

Copilot Builder with Blue iQ

Copilot Builder with Blue iQ

Many fabrication jobs remain beyond the reach of conventional automation because weld conditions are not always predictable. Copilot Builder with Blue iQ uses adaptive intelligence to continuously respond to weld variation in real time, helping fabricators take on more applications without extensive reprogramming or expensive fixtures.

“The value of automation is well established, but many fabrication applications have remained difficult to address with conventional systems where conditions aren’t always predictable,” said Sam Harvey, business unit director, Miller Electric. “Fabricators need solutions that fit the realities of their operations, where part fit-up, joint conditions and production demands can change from one job to the next. With Copilot Builder with Blue iQ, the system can adapt to variation as it occurs, helping manufacturers automate a broader range of welding applications, improve productivity and make better use of their skilled workforce while maintaining the flexibility their operations demand.”

“Fabricators supplying data centers, shipbuilding, energy infrastructure and heavy equipment are facing a growing shortage of skilled welders, programmers and challenges related to part variability in their robotic welding operations. Harnessing our vast amount of welding data, we are excited to bring our Physical AI platform to the Copilot Builder to solve these robotic welding challenges. NovAI™, our AI-powered computer vision solution, performs real-time adaptive welding with no prior joint scanning. Through our partnership, welding automation can now be achieved across a broader range of welding applications,” said Soroush Karimzadeh, CEO and co-founder of Novarc Technologies.

The Copilot Builder with Blue iQ, powered by NovAI™, will be integrated with NovHub™, Novarc’s centralized Enterprise Welding Intelligence platform that brings visibility to robotic and mechanized welding operations by connecting weld data, video, process parameters, and production records. This extends the system’s capabilities by converting production data into actionable insights.

Key technologies within Copilot Builder with Blue iQ, powered by NovAI™, include:

  • NovAI™ Autonomy: Uses machine vision, real-time adaptation and adaptive control to help compensate for gaps, misalignments and part variation during welding.
  • Adaptability to Variation: Designed to address fit-up variability, tack consumption and changing weld conditions without constant reprogramming.
  • Flexible Deployment: Portable system design helps bring robotic welding into existing workspaces rather than requiring parts to fit traditional weld cells.
  • Traceability with NovHub™: Captures and analyzes weld data through a centralized platform that provides insight, traceability and optimization opportunities.

The system can be mounted on horizontal, vertical and inverted surfaces to accommodate different workspaces and part geometries and to better integrate into existing workflows. Remote operation helps improve safety by allowing operators to work farther from heat and fumes, while integrated data supports continuous process improvement over time.

To learn more about how Copilot Builder with Blue iQ helps fabricators address weld variation and expand the range of applications suitable for robotic welding, visit www.millerwelds.com/en-us/automation/welding-automation-systems/copilot.

About Miller

Miller Electric Mfg. LLC, headquartered in Appleton, Wisconsin, is a leading worldwide manufacturer of Miller® brand arc welding products and is a wholly owned subsidiary of Illinois Tool Works Inc. (NYSE: ITW). For more information, visit MillerWelds.com, call 1-800-4-A-Miller (800-426-4553), email [email protected], fax 877-327-8132, or write to Miller Electric Mfg. LLC, P.O. Box 100, Lithonia, GA 30058.

About Novarc Technologies Inc.

Novarc Technologies is the industrial Physical AI company reinventing welding automation for the global fabrication industry by pioneering enterprise welding intelligence. Novarc activates arc welding robots with perception and cognition. With no visual intelligence these industrial robots currently make costly errors that lead to rework, scrap, rebuilds and downtime. Novarc’s Physical AI platform combines real-time computer vision, adaptive control and welding intelligence, with over-the-air software updates to transform robotic welding systems into continuously improving Physical AI endpoints. For more information, visit www.novarc.ai.

Social Media

https://www.facebook.com/MillerWelders

https://www.youtube.com/MillerWelders

https://www.instagram.com/millerwelders/

https://www.linkedin.com/company/MillerWelders

https://www.tiktok.com/@millerweldersofficial

Lauren Smith, Hiebing for Miller

Phone: +1 608.268.4408

[email protected]

Debra Hadden, Novarc Technologies

Phone: +1 604.240.3196

[email protected]

KEYWORDS: Wisconsin United States North America

INDUSTRY KEYWORDS: Machinery Machine Tools, Metalworking & Metallurgy Robotics General Automotive Technology Automotive Artificial Intelligence Other Manufacturing Steel Automotive Manufacturing Aerospace Manufacturing

MEDIA:

Photo
Photo
Copilot Builder with Blue iQ
Logo
Logo
Posted on

The Walt Disney Company to Participate in the Goldman Sachs Communacopia + Technology Conference

The Walt Disney Company to Participate in the Goldman Sachs Communacopia + Technology Conference

BURBANK, Calif.–(BUSINESS WIRE)–
Hugh Johnston, Senior Executive Vice President & Chief Financial Officer, The Walt Disney Company (NYSE: DIS) will participate in a question-and-answer session at the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 9, 2026 at approximately 2:30 p.m. ET/ 11:30 a.m. PT.

To stream live, please visit www.disney.com/investors. A recording of the question-and-answer session will be archived on our website.

Question-and-answer session may include forward-looking information.

Ben Swinburne

Investor Relations

(818) 560-4245

David Jefferson

Corporate Communications

(818) 560-4832

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Entertainment Technology Theme Parks TV and Radio Film & Motion Pictures Other Technology

MEDIA:

Posted on

IPX1031 Named Best Overall 1031 Exchange Company by Fit Small Business for Fifth Consecutive Year

Fit Small Business’s 2026 review recognizes IPX1031 for its nationwide reach, 1031 Exchange capabilities, financial protections, expertise, and value-added services

CHICAGO, Aug. 27, 2026 (GLOBE NEWSWIRE) — Investment Property Exchange Services, Inc. (IPX1031), the national leader in 1031 Qualified Intermediary services, has again been recognized as the Best Overall 1031 Exchange Company by Fit Small Business, marking the fifth consecutive year (2022-2026) the company has received this distinction.

In its 2026 review, Fit Small Business evaluated 1031 Exchange companies based on factors including nationwide coverage, exchange capabilities, insurance protection for exchange funds, educational resources, fees and customer reviews. IPX1031 was selected Best Overall for expertise and value-added services, with the review highlighting its nationwide reach, broad 1031 Exchange capabilities and substantial financial protections.

In addition to Fit Small Business, IPX1031 has consistently been recognized among the industry’s top Qualified Intermediaries by respected publications, including Investopedia, The Balance, Awning, ROI Advisors, and Inside 1031.

“Five consecutive years of recognition reflects what our team delivers every day,” said John Wunderlich, President of IPX1031. “Investors and their advisors need a Qualified Intermediary they can trust when holding their money. We remain committed to providing the financial strength, security, expertise, and service that have defined IPX1031 for nearly 40 years.”

Unlike federally regulated financial institutions, 1031 Exchange Qualified Intermediaries are not federally regulated or licensed in the same manner as banks, making it important for investors and their advisors to understand how exchange funds will be held, managed, and protected.

IPX1031 provides nationwide Qualified Intermediary services for 1031 Exchanges, including Delayed, Simultaneous, Reverse, and Improvement Exchanges. With nearly 40 years of specialized experience, IPX1031’s team includes attorneys, accountants, Certified Exchange Specialists (CES®), and other 1031 Exchange professionals supporting transactions ranging from single investment properties to some of the nation’s most complex commercial and institutional exchanges.

About IPX1031:

Investment Property Exchange Services, Inc. (IPX1031) is the largest and one of the oldest Qualified Intermediaries in the United States. As a wholly owned subsidiary of Fidelity National Financial (NYSE:FNF), a Fortune 500 company, IPX1031 provides industry leading security for exchange funds as well as expertise and experience in facilitating all types of 1031 Exchanges. IPX1031’s nationwide staff, which includes industry experts, veteran attorneys and accountants, is available to provide answers and guidance to clients and their legal and tax advisors. For more information about IPX1031 visit www.ipx1031.com.

For more information, contact:  
Cindi Marinez, VP, Marketing
[email protected]

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4fce396-929c-40b8-9684-bf4e9f3b55ee

 



Posted on

Mint Incorporation Limited Announces Pricing of $2.5 Million Registered Direct Offering

Hong Kong, Aug. 27, 2026 (GLOBE NEWSWIRE) — Mint Incorporation Limited (“Mint” or the “Company”, NASDAQ: MIMI), a Hong Kong-based company with a new strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of an aggregate of 2,500,000 of the Company’s Class A ordinary shares (or prefunded warrants in lieu thereof) with no par value at a purchase price of $1.00 per share. The aggregate gross proceeds to the Company are expected to be approximately $2.5 million, before deducting placement agent fees and other offering expenses.

The transaction is expected to close on or about August 28, 2026, subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the sole placement agent for the offering.

The registered direct offering is being made pursuant to the Company’s registration statement on Form F-3 (File No. 333-296027) previously filed with the U.S. Securities and Exchange Commission (“SEC”), which was declared effective by the SEC on June 3, 2026. A prospectus supplement relating to the securities will be filed by the Company with the SEC. All information filed with the SEC can be obtained over the internet on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745 or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Mint Incorporation Limited

Mint Incorporation Limited (NASDAQ: MIMI) is a Hong Kong-based company listed on NASDAQ, strategically focused on artificial intelligence (AI), robotics, and interior design. Through its wholly-owned subsidiary Axonex AI Limited (“Axonex AI”), and through Aspiration X Limited’s joint venture Rice Robotics AGI Holding Limited (“Rice Robotics AGI”), Mint delivers comprehensive intelligent automation solutions. Axonex AI specializes in smart facility management, integrating robotics, IoT, physical AI solutions such as humanoid robots and AI-powered analytics to provide real-time monitoring and predictive insights. Rice Robotics AGI focuses on customer-centric robots and companion robots. In addition, through Matter International Limited, the Group provides professional interior design and fit-out services. Anchored by innovation and practical application, Mint is committed to enhancing efficiency, safety, and quality of life across industries.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions, and includes such statements regarding timing of closing, satisfaction of closing conditions, and expected proceeds from the offering. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.

For Media and Investor Inquiries

Mint Incorporated Limited
Email: [email protected]
Telephone: +852 2866 1663 



Posted on

UPDATE — Canada-Japan Support Advances Xanadu and Mitsubishi Chemical Partnership on Quantum Semiconductor Research

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) — Xanadu Quantum Technologies Limited (“Xanadu“; NASDAQ/TSX: XNDU), a leading photonic quantum computing company, has announced the next phase of its collaboration with Mitsubishi Chemical, a major Japanese chemical manufacturer, to advance semiconductor fabrication technologies using quantum computing algorithms. This next phase is supported by national innovation programs from both the Canadian and Japanese governments, aiming to scale Xanadu and Mitsubishi’s previous work in simulating a vital process in next-generation semiconductor fabrication: extreme ultraviolet (EUV) lithography. Bringing together both Canadian and Japanese expertise in quantum computing and materials science, this collaboration underscores a shared commitment to driving global innovation in the semiconductor industry through quantum technologies.

EUV lithography enables the creation of powerful chips used across multiple industries, such as mobile, AI, and advanced computing, and is crucial for current and next-generation semiconductor manufacturing. However, its efficiency is often hindered by radiation-induced blurring, an inherently quantum phenomenon that remains a major bottleneck for classical simulations. In phase one of Xanadu and Mitsubishi’s collaboration, the two companies demonstrated that quantum algorithms can accurately model key aspects of EUV lithography, specifically the optical properties of the photoresists used to etch lithographic patterns. The next phase of the collaboration aims to develop an industry-oriented workflow that will take parameters derived from Xanadu’s quantum computing simulations and integrate them directly into Mitsubishi’s multi-scale models to predict blur. The result will be a fault-tolerant quantum computing (FTQC)-ready software pipeline designed to identify materials that prevent blurring and support the development of semiconductor materials for next-generation manufacturing.

Xanadu plans to provide a concrete demonstration and roadmap for how quantum computing can contribute to the development of EUV resist materials through this collaboration. This second phase of the collaboration is being advanced with support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) and from Japan’s Strategic Innovation Promotion Program (SIP). The relevant SIP project is led by the National Institute of Advanced Industrial Science and Technology (AIST) and the Global Research and Development Center for Business by Quantum-AI Technology (G-QuAT). The collaboration aims to further strengthen research and business collaboration between the two countries’ technology sectors.

Xanadu has previously received advisory services and more than $800,000 in funding from NRC IRAP, supporting its R&D in quantum computing across several projects, which helped lay the groundwork for this advancement.

“Our collaboration with Mitsubishi bridges quantum simulation and semiconductor fabrication, eliminating a critical manufacturing bottleneck and supporting the development of differentiated semiconductor materials for next-generation manufacturing. The support from the Canadian and Japanese national innovation programs underscores the importance of this partnership to advance the semiconductor industry globally,” said Dr. Christian Weedbrook, Founder and Chief Executive Officer of Xanadu.

“This partnership expands on Mitsubishi’s previously successful collaboration with Xanadu, where we demonstrated the utility of quantum computing in simulating EUV resist materials for semiconductor manufacturing,” said Dr. Qi Gao, Distinguished Scientist, Analysis Technology Laboratory, Mitsubishi Chemical Corporation. “With support from national innovation programs and research organizations in both countries, we’re excited to bring together Canadian and Japanese expertise in quantum computing and materials science.”

“This project is a great example of connecting cutting-edge quantum computing research with real industrial challenges. In the critical field of semiconductor materials development, we expect this Japan-Canada collaboration to accelerate the real-world implementation of quantum technology. At SIP, we look forward to the new industrial value this initiative will create,” said Dr. Masahiro Horibe, Sub-Program Director, Cross-ministerial SIP and Deputy Director, G-QuAT, AIST.

This shared initiative between Xanadu and Mitsubishi aims to showcase quantum computing innovation on the world stage while advancing critical quantum simulation capabilities for the global semiconductor industry. By bridging quantum innovation with industrial application, this continued partnership will establish a blueprint for quantum-driven material discovery. As Xanadu and Mitsubishi Chemical advance this joint pipeline, their work aims to unlock commercial value for early FTQC systems, while driving the future of global semiconductor fabrication.

About Xanadu

Founded in 2016, Xanadu is a Canadian photonic quantum computing company with the mission to build quantum computers that are useful and available to people everywhere. Xanadu is building fault-tolerant quantum computers using light, with systems designed to compute at room temperature. Xanadu develops both hardware and software, including PennyLane, its open-source quantum computing platform. Xanadu is the first pure-play photonic quantum computing company to list on public markets (Nasdaq/TSX: XNDU) and is recognized globally for its breakthroughs in scalable quantum technologies. Visit xanadu.ai or follow on X @XanaduAI.

Press Contact:


[email protected]

Investor Relations:


[email protected]

About Mitsubishi Chemical

Mitsubishi Chemical Corporation, established in 1933, is a comprehensive chemical manufacturer that provides a wide range of materials, from basic chemicals to performance products. The company operates globally across diverse fields including mobility, semiconductors and communications, food, medical, and infrastructure. Mitsubishi Chemical aims to be a “Green Specialty Company” committed to solving social problems and to delivering impressive results to customers with the power of materials, under our Purpose that “We lead with innovative solutions to achieve KAITEKI, the well-being of people and the planet.” For further information, please visit our website:


https://www.m-chemical.co.jp/en/index.html

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the U.S. federal securities laws and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. We have based these forward-looking statements on current expectations and projections about future events. These statements include: statements regarding potential funding and support from Canadian and Japanese national innovation programs.; expectations regarding Xanadu and Mitsubishi’s ability to simulate extreme ultraviolet (EUV) lithography processes in next-generation semiconductor fabrication; Xanadu’s ability to bring its technology to market; Xanadu’s ability to scale its technology platform and advance toward practical, real-world use cases; Xanadu’s ability to accelerate its commercial roadmap and leadership in photonic quantum computing; beliefs regarding the potential of light-based quantum systems to offer a path to scalable, fault-tolerant quantum computing; and Xanadu’s mission to build quantum computers that are useful and available to people everywhere.

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of Xanadu. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause the actual results of the combined company following the transaction, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such statements. Such risks and uncertainties include: that Xanadu is pursuing an emerging technology, faces significant technical challenges and may not achieve commercialization or market acceptance; Xanadu’s historical net losses and limited operating history; that there is substantial doubt about Xanadu’s ability to continue as a going concern; Xanadu’s expectations regarding future financial performance, capital requirements and unit economics; Xanadu’s use and reporting of business and operational metrics; Xanadu’s competitive landscape; Xanadu’s dependence on members of its senior management and its ability to attract and retain qualified personnel; the potential need for additional future financing; Xanadu’s ability to manage growth and expand its operations; potential future acquisitions or investments in companies, products, services or technologies; Xanadu’s reliance on strategic partners and other third parties; Xanadu’s concentration of revenue in contracts with government or state-funded entities; Xanadu’s ability to maintain, protect and defend its intellectual property rights; risks associated with privacy, data protection or cybersecurity incidents and related regulations; the use, rate of adoption, and regulation of artificial intelligence and machine learning; uncertainty or changes with respect to laws and regulations; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic environment; material weaknesses in Xanadu’s internal control over financial reporting and the combined company’s ability to maintain internal control over financial reporting and operate as a public company; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings or government investigations that may be commenced against Xanadu; failure to realize the anticipated benefits of the transaction; the ability of the combined company to issue equity or equity-linked securities in the future; and other factors described in Xanadu’s filings with the SEC (www.sec.gov) and the Canadian Securities Administrators (www.sedarplus.com). These forward-looking statements are based on certain assumptions, including that none of the risks identified above materialize; that there are no unforeseen changes to economic and market conditions, and that no significant events occur outside the ordinary course of business. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by Xanadu with the SEC and the Canadian Securities Administrators, including under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, these statements reflect the expectations, plans and forecasts of Xanadu’s management as of the date of this communication; subsequent events and developments may cause their assessments to change. While Xanadu may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so, unless required by applicable securities laws. Accordingly, undue reliance should not be placed upon these statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this communication, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.